WO2026053159 - DAZOSTINAG OR CONJUGATES THEREOF FOR TREATMENT OF ADENOID CYSTIC CARCINOMAS
National phase entry is expected:
Publication Number
WO/2026/053159
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058947
International Filing Date
05.09.2025
Title **
[English]
DAZOSTINAG OR CONJUGATES THEREOF FOR TREATMENT OF ADENOID CYSTIC CARCINOMAS
[French]
DAZOSTINAG OU SES CONJUGUÉS POUR LE TRAITEMENT DES CARCINOMES ADÉNOÏDES KYSTIQUES
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
HUANG, Harry
LINEBERRY, Neil
RAIZER, Jeffrey
Inventors
HUANG, Harry
LINEBERRY, Neil
RAIZER, Jeffrey
Priority Data
63/691,937
06.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3171 | |
| EPO | Filing, Examination, Granting | 26670 | |
| Japan | Filing, Examination, Granting | 3261 | |
| South Korea | Filing, Examination, Granting | 4176 | |
| USA | Filing, Examination, Granting | 11340 |
Total:
48,618
Contact Us
Abstract[English]
The present disclosure provides a method of treating an adenoid cystic carcinoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of dazostinag or ADC-B17, or a pharmaceutically acceptable salt thereof, and optionally, an immune checkpoint inhibitor.[French]
La présente divulgation concerne une méthode de traitement d'un carcinome adénoïde kystique chez un sujet en ayant besoin, la méthode comprenant l'administration au sujet d'une quantité thérapeutiquement efficace de dazostinag ou d'ADC-B17, ou d'un sel pharmaceutiquement acceptable de ceux-ci, et facultativement, d'un inhibiteur de point de contrôle immunitaire.